Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000177 · ClinicalTrials.gov registry record · Phase 3

Estrogen Hormone Protocol

A Phase 3 study, sponsored by National Institute on Aging (NIA).

Completed
Registry status
Phase 3
Development phase
120
Enrollment target

NCT00000177 is a Phase 3 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 120 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000177, a Phase 3 study, has completed, sponsored by National Institute on Aging (NIA).

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target

Study Summary

Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.

Interventions

  • DRUG Estrogen

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 1995-10
Est. Completion 1999-01
Phase Phase 3

Sponsor

National Institute on Aging (NIA)

131 total trials

What the Registry Record Tells You About NCT00000177

The ClinicalTrials.gov registry entry for NCT00000177 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Estrogen is the first listed.

NCT00000177 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00000177 about?

NCT00000177 is a clinical study titled "Estrogen Hormone Protocol". Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatm...

What is the current status of trial NCT00000177?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 1995-10. Estimated completion is 1999-01.

What interventions are being tested in trial NCT00000177?

The interventions under investigation include: Estrogen (DRUG).

Who is sponsoring clinical trial NCT00000177?

This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.